On the 26th morning, Alteogen shares were up in the 4% range after news that it signed an option contract for ALT-B4 technology transfer with a global pharmaceutical company.
As of 9:04 a.m. that day, Alteogen was trading on the KOSDAQ market at 447,500 won, up 17,500 won (4.07%) from the previous session.
Earlier, Alteogen posted on its website that it had signed an option contract with a global pharmaceutical company for ALT-B4, a product for switching to a subcutaneous injection formulation. It said the company and product names were agreed to be undisclosed due to the competitive landscape of the counterparty's products.
Alteogen said, "Under the option contract signed by the two companies, the partner will receive data to begin clinical development by using our ALT-B4 for its currently marketed product and will pay option fees to Alteogen," adding, "Depending on development progress, the final technology transfer agreement will be decided within 2026."
It added, "This option contract is separate from the license-out contract (license agreement) in the late stage that the new partner and our company are pursuing, and that contract is also in the final coordination of detailed terms and is expected to be concluded smoothly."